Shares of Repligen Co. (NASDAQ:RGEN) have been assigned a consensus recommendation of “Buy” from the ten brokerages that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $56.40.
Several equities analysts have commented on RGEN shares. Zacks Investment Research upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $62.00 price target for the company in a research note on Thursday, October 4th. BidaskClub downgraded shares of Repligen from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 25th. Janney Montgomery Scott restated a “buy” rating on shares of Repligen in a research note on Thursday, October 4th. HC Wainwright started coverage on shares of Repligen in a research note on Wednesday, September 26th. They issued a “neutral” rating and a $49.00 price target for the company. Finally, ValuEngine upgraded shares of Repligen from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 23rd.
Repligen stock traded up $1.07 during trading on Monday, hitting $67.29. The company had a trading volume of 1,016,563 shares, compared to its average volume of 332,218. The company has a market capitalization of $2.90 billion, a PE ratio of 97.52, a price-to-earnings-growth ratio of 5.22 and a beta of 0.74. Repligen has a 1-year low of $29.56 and a 1-year high of $68.12.
Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, November 1st. The biotechnology company reported $0.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.18 by $0.02. The business had revenue of $49.53 million during the quarter, compared to the consensus estimate of $46.69 million. Repligen had a net margin of 12.61% and a return on equity of 5.39%. The company’s quarterly revenue was up 35.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.15 earnings per share. As a group, research analysts predict that Repligen will post 0.73 earnings per share for the current year.
In other news, CEO Anthony Hunt sold 27,566 shares of Repligen stock in a transaction on Monday, September 10th. The shares were sold at an average price of $57.71, for a total transaction of $1,590,833.86. Following the completion of the sale, the chief executive officer now directly owns 255,017 shares of the company’s stock, valued at approximately $14,717,031.07. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Roy T. Eddleman sold 4,770 shares of Repligen stock in a transaction on Wednesday, August 8th. The stock was sold at an average price of $49.05, for a total transaction of $233,968.50. Following the sale, the insider now directly owns 413,985 shares of the company’s stock, valued at $20,305,964.25. The disclosure for this sale can be found here. In the last 90 days, insiders sold 55,742 shares of company stock valued at $3,068,068. Insiders own 1.40% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new stake in shares of Repligen during the 2nd quarter worth $135,000. Seven Eight Capital LP purchased a new stake in shares of Repligen during the 3rd quarter worth $217,000. Smith Asset Management Group LP lifted its position in shares of Repligen by 1,511.8% during the 2nd quarter. Smith Asset Management Group LP now owns 4,658 shares of the biotechnology company’s stock worth $219,000 after purchasing an additional 4,369 shares during the last quarter. Benin Management CORP purchased a new stake in shares of Repligen during the 2nd quarter worth $235,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of Repligen during the 2nd quarter worth $250,000. 93.08% of the stock is owned by institutional investors and hedge funds.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Further Reading: When is a capital gain realized?
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.